$FBRX News

Forte Biosciences Files $500M Shelf Registration For Potential Issuance Of Common Stock, Preferred Stock, Debt Securities, Warrants, And Other Securities From Time To Time

Forte Biosciences Q1 EPS $(1.24) Misses $(1.19) Estimate

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.

Forte Biosciences shares are trading higher. The company announced the pricing of its $150 million offering of 5.7 million shares at 26.27 per share.

Reported Earlier, Forte Biosciences Prices $150M Public Offering Of 5.7M Shares At $26.27 Per Share To Fund Clinical Development Of Autoimmune Disease Candidate FB102

Forte Biosciences shares are trading lower after the company announced a proposed public offering.

Forte Biosciences Reveals Proposed Public Offering; No Size Disclosed

Forte Biosciences Q4 EPS $(1.45) Misses $(1.06) Estimate

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know

We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year

Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price Target of $65

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update